Search - tctmd.com

Displaying 1 - 20 of 77

Sort: Relevancy | Date

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

News Daily News

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

February 02, 2026

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

Benefits of SGLT2 Inhibitors for HF Affirmed in Large, Real-world Study

News Daily News

Benefits of SGLT2 Inhibitors for HF Affirmed in Large, Real-world Study

May 09, 2025

March 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

March 2025 Dispatch for the CV Team

March 21, 2025

Sotagliflozin Reduces Ischemic Risk in SCORED Analysis

News Daily News

Sotagliflozin Reduces Ischemic Risk in SCORED Analysis

Yael L. Maxwell

February 25, 2025

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

News Conference News THT 2025

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

February 12, 2025

January 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

January 24, 2025

Top Heart Failure News of 2024

News Daily News

Top Heart Failure News of 2024

December 31, 2024

December 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

December 2024 Dispatch for the CV Team

December 20, 2024

November 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

November 26, 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

News Conference News AHA 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Michael O'Riordan

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

News Daily News

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

August 05, 2024

Semaglutide Has Similar Benefits in Women and Men With HFpEF

News Daily News

Semaglutide Has Similar Benefits in Women and Men With HFpEF

June 26, 2024

May 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

May 2024 Dispatch for the CV Team

May 01, 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

April 06, 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

April 06, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.